Anne Tham1, Ulf Jonsson2, Gerhard Andersson3, Anne Söderlund4, Per Allard5, Göran Bertilsson6. 1. Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Stockholm, Sweden. 2. Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Neuroscience, Child and Adolescent Psychiatry, Uppsala University, Uppsala, Sweden. 3. Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Stockholm, Sweden; Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden. 4. School of Health, Care and Social Welfare, Physiotherapy, Mälardalen University, Västerås, Sweden. 5. Swedish Agency for Health Technology Assessment and Assessment of Social Services, Stockholm, Sweden. 6. Swedish Agency for Health Technology Assessment and Assessment of Social Services, Stockholm, Sweden. Electronic address: goran.bertilsson@sbu.se.
Abstract
BACKGROUND: There has been a steady increase in the prescription of antidepressants for the elderly. This study comprises a systematic review of randomized, placebo-controlled trials of antidepressants for treatment of depressive disorder in people aged 65 years or more. METHODS: PubMed, EMBASE, Cochrane Library, CINAL, and PsycINFO were searched until May 2016. Where appropriate, the results were synthesized in meta-analyses. RESULTS: Twelve trials met the inclusion criteria. For patients with major depressive disorder, selective serotonin re-uptake inhibitors (SSRI) were not superior to placebo in achieving remission (OR: 0.79, 95% CI: 0.61-1.03) or response (OR=0.86, 95% CI: 0.51-1.10) after 8 weeks of treatment (three trials). However, maintenance treatment with SSRIs was superior to placebo in preventing relapse (OR: 0.22, 95% CI: 0.13-0.36; NNT=5, 95% CI: 3-6; two trials). Duloxetine was superior to placebo in achieving remission (OR: 1.78, 95% CI: 1.20-2.65; NNT=9, 95% CI: 6-20; three trials) and response (OR: 1.83, 95% CI: 1.96-4.08; two trials) in recurrent major depression after 8 weeks, but increased the risk of adverse events that can be problematic in the elderly. LIMITATIONS: The quality of evidence was generally low or moderate, emphasizing the uncertainty of the results. Study populations only partly covered the heterogeneous population of elderly with depressed mood, limiting the generalizability. CONCLUSION: The results underscore the importance of close monitoring of the effects of antidepressants in treatment of elderly patients with a depressive disorder. Methods for early detection of non-responders and effective treatment options for this group are needed.
BACKGROUND: There has been a steady increase in the prescription of antidepressants for the elderly. This study comprises a systematic review of randomized, placebo-controlled trials of antidepressants for treatment of depressive disorder in people aged 65 years or more. METHODS: PubMed, EMBASE, Cochrane Library, CINAL, and PsycINFO were searched until May 2016. Where appropriate, the results were synthesized in meta-analyses. RESULTS: Twelve trials met the inclusion criteria. For patients with major depressive disorder, selective serotonin re-uptake inhibitors (SSRI) were not superior to placebo in achieving remission (OR: 0.79, 95% CI: 0.61-1.03) or response (OR=0.86, 95% CI: 0.51-1.10) after 8 weeks of treatment (three trials). However, maintenance treatment with SSRIs was superior to placebo in preventing relapse (OR: 0.22, 95% CI: 0.13-0.36; NNT=5, 95% CI: 3-6; two trials). Duloxetine was superior to placebo in achieving remission (OR: 1.78, 95% CI: 1.20-2.65; NNT=9, 95% CI: 6-20; three trials) and response (OR: 1.83, 95% CI: 1.96-4.08; two trials) in recurrent major depression after 8 weeks, but increased the risk of adverse events that can be problematic in the elderly. LIMITATIONS: The quality of evidence was generally low or moderate, emphasizing the uncertainty of the results. Study populations only partly covered the heterogeneous population of elderly with depressed mood, limiting the generalizability. CONCLUSION: The results underscore the importance of close monitoring of the effects of antidepressants in treatment of elderly patients with a depressive disorder. Methods for early detection of non-responders and effective treatment options for this group are needed.
Authors: Ian R Kleckner; Charles Kamen; Jennifer S Gewandter; Nimish A Mohile; Charles E Heckler; Eva Culakova; Chunkit Fung; Michelle C Janelsins; Matthew Asare; Po-Ju Lin; Pavan S Reddy; Jeffrey Giguere; Jeffrey Berenberg; Shelli R Kesler; Karen M Mustian Journal: Support Care Cancer Date: 2017-12-14 Impact factor: 3.603
Authors: Aliza P Wingo; Eric R Velasco; Antonio Florido; Adriana Lori; Dennis C Choi; Tanja Jovanovic; Kerry J Ressler; Raül Andero Journal: Biol Psychiatry Date: 2017-08-30 Impact factor: 13.382
Authors: Faiza Siddiqui; Marija Barbateskovic; Sophie Juul; Kiran Kumar Katakam; Klaus Munkholm; Christian Gluud; Janus Christian Jakobsen Journal: Syst Rev Date: 2021-06-09
Authors: Ulf Jonsson; Göran Bertilsson; Per Allard; Harald Gyllensvärd; Anne Söderlund; Anne Tham; Gerhard Andersson Journal: PLoS One Date: 2016-08-18 Impact factor: 3.240